Segment Information (Tables)

3 Months Ended

Mar. 31, 2019

Schedule of net product sales, cost of product sales and gross profit for each commercial products

Net product sales, cost of product sales and gross profit for each of our commercial products were as follows (in millions):


	Three Months Ended March 31,
2019	Remodulin		Tyvaso		Orenitram		Unituxin		Adcirca		Total
Net product sales	$	155.5	$	103.8	$	58.4	$	24.9	$	20.0	$	362.6
Cost of product sales		6.1		4.4		4.8		5.1		8.7		29.1
Gross profit	$	149.4	$	99.4	$	53.6	$	19.8	$	11.3	$	333.5

2018
Net product sales	$	126.8	$	94.6	$	52.2	$	18.0	$	97.6	$	389.2
Cost of product sales		3.0		3.0		3.0		2.3		41.9		53.2
Gross profit	$	123.8	$	91.6	$	49.2	$	15.7	$	55.7	$	336.0

Schedule of net revenues from external customers by geographic area

Geographic revenues are determined based on the country in which our customers (distributors) are located. Total revenues from external customers by geographic area are as follows (in millions):


	Three Months Ended March 31,
	2019		2018
United States	$	329.5	$	365.8
Rest-of-World(1)		33.1		23.4
Total	$	362.6	$	389.2

(1)Primarily Europe.